Qian Zhang1, Zhi-Qing Li, Hu Liu, Jia-He Yang. 1. Qian Zhang, Department of Infectious Diseases, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Abstract
AIM: To investigate the inhibitory effect of hepatitis B virus (HBV) preS2 antibody (preS2Ab) against HBV infection and HBV-associated hepatic carcinogenesis. METHODS: An adenoviral vector carrying the full-length light and heavy chains of the HBV preS2Ab gene, Ad315-preS2Ab, was constructed. Enzyme linked immunosorbent assay (ELISA) and Western blotting analyses were used to determine the preS2Ab expression levels in vitro. Immunofluorescent techniques were used to examine the binding affinity between the expressed HBV preS2Ab and HBV-positive liver cells. ELISAs were also used to determine hepatitis B surface antigen (HBsAg) levels to assess the inhibitory effect of the preS2Ab against HBV infection in L02 cells. The inhibitory effect of preS2Ab against hepatic carcinogenesis was studied with diethylnitrosamine (DEN)-induced hepatocellular carcinomas (HCCs) in HBV transgenic mice. RESULTS: The expression of HBV preS2Ab increased with increases in the multiplicity of infection (MOI) of Ad315-preS2Ab in L02 cells, with 350.87 ± 17.37 μg/L of preS2Ab when the MOI was 100 plaque forming units (pfu)/cell. The expressed preS2Abs could recognize liver cells from HBV transgenic mice. ELISA results showed that L02 cells expressing preS2Ab produced less HBsAg after treatment with the serum of HBV patients than parental L02 cells expressing no preS2Ab. HBV transgenic mice treated with Ad315-preS2Ab had fewer and smaller cancerous nodes after induction with DEN than mice treated with a blank Ad315 vector or untreated mice. Additionally, the administration of Ad315-preS2Ab could alleviate hepatic cirrhosis and decrease the serum levels of alanine transaminase and aspartate transaminase. CONCLUSION: Adenovirus-mediated HBV preS2Ab expression could inhibit HBV infection in L02 cells, and then inhibit DEN-induced hepatocellular carcinogenesis and protect hepatic function in HBV transgenic mice.
AIM: To investigate the inhibitory effect of hepatitis B virus (HBV) preS2 antibody (preS2Ab) against HBV infection and HBV-associated hepatic carcinogenesis. METHODS: An adenoviral vector carrying the full-length light and heavy chains of the HBVpreS2Ab gene, Ad315-preS2Ab, was constructed. Enzyme linked immunosorbent assay (ELISA) and Western blotting analyses were used to determine the preS2Ab expression levels in vitro. Immunofluorescent techniques were used to examine the binding affinity between the expressed HBVpreS2Ab and HBV-positive liver cells. ELISAs were also used to determine hepatitis B surface antigen (HBsAg) levels to assess the inhibitory effect of the preS2Ab against HBV infection in L02 cells. The inhibitory effect of preS2Ab against hepatic carcinogenesis was studied with diethylnitrosamine (DEN)-induced hepatocellular carcinomas (HCCs) in HBVtransgenic mice. RESULTS: The expression of HBVpreS2Ab increased with increases in the multiplicity of infection (MOI) of Ad315-preS2Ab in L02 cells, with 350.87 ± 17.37 μg/L of preS2Ab when the MOI was 100 plaque forming units (pfu)/cell. The expressed preS2Abs could recognize liver cells from HBVtransgenic mice. ELISA results showed that L02 cells expressing preS2Ab produced less HBsAg after treatment with the serum of HBVpatients than parental L02 cells expressing no preS2Ab. HBVtransgenic mice treated with Ad315-preS2Ab had fewer and smaller cancerous nodes after induction with DEN than mice treated with a blank Ad315 vector or untreated mice. Additionally, the administration of Ad315-preS2Ab could alleviate hepatic cirrhosis and decrease the serum levels of alanine transaminase and aspartate transaminase. CONCLUSION: Adenovirus-mediated HBVpreS2Ab expression could inhibit HBV infection in L02 cells, and then inhibit DEN-induced hepatocellular carcinogenesis and protect hepatic function in HBVtransgenic mice.
Authors: Janja Ocvirk; Thomas Brodowicz; Fritz Wrba; Tudor E Ciuleanu; Galina Kurteva; Semir Beslija; Ivan Koza; Zsuzsanna Pápai; Diethelm Messinger; Ugur Yilmaz; Zsolt Faluhelyi; Suayib Yalcin; Demetris Papamichael; Miklós Wenczl; Zrinka Mrsic-Krmpotic; Einat Shacham-Shmueli; Damir Vrbanec; Regina Esser; Werner Scheithauer; Christoph C Zielinski Journal: World J Gastroenterol Date: 2010-07-07 Impact factor: 5.742
Authors: L Ochoa-Callejero; I Otano; A Vales; C Olagüe; P Sarobe; J J Lasarte; J Prieto; S Menne; G González-Aseguinolaza Journal: Vaccine Date: 2010-07-19 Impact factor: 3.641
Authors: Márcio A Menezes; Karina A Aires; Christiane Y Ozaki; Renato M Ruiz; Milton Ca Pereira; Patrícia Ae Abreu; Waldir P Elias; Oscar Hp Ramos; Roxane Mf Piazza Journal: BMC Res Notes Date: 2011-02-02
Authors: Johan Rebetz; Manli Na; Changqing Su; Bo Holmqvist; Anna Edqvist; Cecilia Nyberg; Bengt Widegren; Leif G Salford; Hans Olov Sjögren; Niklas Arnberg; Qijun Qian; Xiaolong Fan Journal: PLoS One Date: 2009-12-29 Impact factor: 3.240